SOURCE: TheraBiogen, Inc.

January 13, 2011 08:45 ET

TheraBiogen, Inc. Announces Completion of Initial Market Launch With Rite Aid and Follow on Reorders for Its TheraMax® Products, Including Cold and Flu Relief and Allergy Relief

NEW YORK, NY--(Marketwire - January 13, 2011) - TheraBiogen, Inc. (OTCBB: TRAB) announced it is shipping reorders to Rite Aid Pharmacy to replenish their stores nationally.

TheraBiogen has been selling TheraMax® Cold & Flu Relief and TheraMax® Allergy Relief since the beginning of the 2010 Fall Season for cold and flu relief. Since the original national sales release in October 2010, TheraMax® products have, through a joint promotion between Rite Aid and TheraBiogen, sold out in most Rite Aid stores, and Rite Aid has placed additional orders to replenish its stock of TheraMax® products. Both nasal spray products are available at all of the pharmacy chain's retail locations. Consumers nationwide have embraced the new products in their initial launch. Kelly Hickel, CEO of TheraBiogen, Inc., said "We are very excited at the enthusiastic reception both by Rite Aid management and consumers. As we expand distribution, we expect to see that same great support from consumers."

About TheraBiogen, Inc.

TheraBiogen, Inc. is the manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies and cold and flu symptoms. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules.

Contact Information

  • Company Contact:
    TheraBiogen, Inc.
    Kelly T. Hickel
    Chairman and CEO
    646-808-3095
    Email Contact